Asia Pacific Pharmaceutical (002370.SZ): Spironolactone tablets passed the consistent evaluation of generic drug quality and efficacy

Zhitong Finance App News, Asia Pacific Pharmaceutical (002370.SZ) issued an announcement. The company recently received the “Drug Supplement Application Approval Notice” for spironolactone tablets approved and issued by the State Drug Administration. The company's spironolactone tablets passed the consistent evaluation of the quality and efficacy of generic drugs. Spironolactone tablets are suitable for the prevention of edematous diseases, hypertension, primary hyperaldosteronism and hypokalemia.

Through the consistent evaluation of generic drug quality and efficacy, spironolactone tablets will further enrich the company's product pipeline, help enhance the competitiveness of this drug market, and accumulate experience in carrying out generic drug consistency evaluation work for the company's subsequent other products.